Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.

¹ Clinical Microbiology, The Chaim Sheba Medical Centre, Ramat-Gan, Israel; Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
² Infection Control and Prevention Unit, The Chaim Sheba Medical Centre, Ramat-Gan, Israel; The Gertner Institute for Epidemiology and Health Policy Research, The Chaim Sheba Medical Centre, Ramat-Gan, Israel; Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ General Management, The Chaim Sheba Medical Centre, Ramat-Gan, Israel; Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁴ Infectious Diseases Unit, The Chaim Sheba Medical Centre, Ramat-Gan, Israel; Sakler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: [email protected].

No abstract available

Publication types

BNT162 Vaccine
COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 / transmission
COVID-19 Vaccines / therapeutic use*
Humans
Infectious Disease Transmission, Patient-to-Professional / prevention & control*
Israel / epidemiology
Mass Vaccination*
Medical Staff, Hospital*
Pandemics / prevention & control*
Retrospective Studies
SARS-CoV-2